How should patients with severe side effects of sotoracib (AMG 510) adjust their medication regimen?

Sotorasib (trade name: AMG 510) is one of the first targeted drugs approved for KRAS G12C mutated non-small cell lung cancer (NSCLC) and has shown significant efficacy in clinical trials. However, some patients may experience varying degrees of side effects during use, and the medication regimen needs to be adjusted in a targeted manner to ensure efficacy while reducing the risk of adverse reactions. The following is a comprehensive analysis from the aspects of side effect characteristics, dose adjustment principles, monitoring strategies and individualized management.

First of all, common adverse reactions of sotorasiib include mild to moderate diarrhea, nausea, fatigue, abnormal liver function (such as ALT, AST elevation), anemia, and rash. Clinical data shows that most side effects are grade 1 to 2 and can be alleviated through symptomatic treatment, but a small number of patients may still experience serious adverse events of grade 3 or above, such as severe liver function damage, interstitial lung disease or significant hematological abnormalities. For these patients with severe side effects, the severity of their symptoms and impact on their quality of life must be promptly assessed to ensure safe medication use.

For patients with severe side effects, the main principles of medication adjustment for sotoraxib include suspending medication, reducing the dose, or extending the dosing interval. Specifically, when a patient experiences liver function abnormalities of grade 3 or above or severe diarrhea, rash, etc., the drug should be suspended immediately. After the symptoms have significantly improved to grade 1 or returned to a state close to the baseline, medication should be resumed according to the patient's tolerance, and the dose can be appropriately reduced. For example, patients whose original dose is 960 mg once daily may consider adjusting to 720 mg or 480 mg once daily, and hematological and biochemical indicators should be closely monitored during recovery. In addition, for patients with hepatic and renal insufficiency or underlying diseases, a comprehensive evaluation should be conducted before the first dose, and the dose should be flexibly adjusted according to individual responses during treatment.

Regular monitoring and follow-up are particularly critical during the management of side effects. It is recommended that patients undergo liver function, blood routine and renal function tests every 2 to 4 weeks before treatment and at the beginning of treatment. Subsequently, the monitoring interval can be extended according to the patient's status. For patients who experience mild to moderate side effects, symptoms can be alleviated through dietary adjustments, fluid rehydration, antiemetic drugs, antidiarrheal drugs, or skin care, while psychological support and health education can be strengthened to improve patient compliance. For severe side effects or recurrent adverse events, multidisciplinary collaboration, including oncology, hepatology, nutrition and pharmacy experts, needs to be considered to jointly develop an individualized medication plan.

In addition, individualized dosing strategies are important in the long-term use of sotoraxib. Some patients may have different drug sensitivities due to genetic background, concomitant medication, or physical differences. Therefore, during the medication process, the dosage, medication interval, or auxiliary drugs should be flexibly adjusted based on the patient's treatment response and side effects, and the efficacy and tolerability after each adjustment should be recorded and evaluated. This not only helps to maximize the anti-tumor effect of sotorasib, but also significantly reduces the risk of patients interrupting treatment due to side effects.

To sum up, patients with severe side effects of sotorasib should follow the principle of "timely suspension - improvement of symptoms - individualized dose adjustment - close monitoring" and achieve maximum efficacy and safety through scientific management of side effects and reasonable adjustment of medication regimens. At the same time, patients and their families should actively cooperate with clinical follow-up and monitoring to achieve early detection and early treatment to ensure the continued benefit of sotoraxib in the treatment of KRAS G12C mutation NSCLC .

Reference materials:https://www.drugs.com/